ExonHit is a fast emerging healthcare player developing innovative molecular diagnostic tests and therapeutics for neurodegenerative and cancer indications. The Company is listed on Alternext of NYSE Euronext Paris.
Navigation
 |
Corinne Hoff Director, Communication & Investor Relations Direct line: +33 1 58 05 47 04 ExonHit Therapeutics S.A.
|
For non-media-related enquiries, please call ExonHit’s switchboard at +33 1 53 94 77 00